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Acute Intravenous Injection of Serelaxin (Recombinant Human
Relaxin-2) Causes Rapid and Sustained Bradykinin-Mediated
Vasorelaxation
Chen Huei Leo, PhD; Maria Jelinic, MSc; Helena C. Parkington, PhD; Marianne Tare, PhD; Laura J. Parry, PhD
Background-—A recent clinical trial (RELAXin in Acute Heart Failure [RELAX-AHF]) demonstrated that 48 hours of continuous
intravenous infusion of the vasorelaxant peptide serelaxin (recombinant human relaxin-2) to patients with acute heart failure
reduced cardiovascular mortality at 180 days. The persistence of a vasorelaxant response as a potential mechanism for this long-
term benefit and the vascular effects of a bolus intravenous injection of serelaxin have not been examined. This study investigates
changes in resistance artery reactivity and passive mechanical wall properties following an intravenous serelaxin injection and
whether these vascular effects persist in the absence of detectable circulating serelaxin.
Methods and Results-—Male rats were injected with 13.3 lg/kg serelaxin into the tail vein; mesenteric arteries were assessed 3
and 24 hours after treatment by using wire-myography. Serelaxin increased basal nitric oxide synthase activity and reduced
maximal contraction to endothelin-1 at 3 hours after administration. Serelaxin treatment also selectively enhanced bradykinin-
mediated endothelium-dependent relaxation. This effect was sustained for 24 hours in the absence of circulating serelaxin.
Serelaxin-mediated augmentation of bradykinin-evoked relaxation involved endothelium-derived hyperpolarization after 3 hours
and prostacyclin-mediated relaxation after 24 hours. Furthermore, upregulation of inducible nitric oxide synthase, phosphorylation
of protein kinase B at Ser473 and endothelial nitric oxide synthase at Ser1177 was observed at 24 hours after serelaxin injection.
There were no effects of serelaxin on passive arterial wall stiffness.
Conclusion-—Our data show that a bolus intravenous injection of serelaxin modulates endothelial vasodilator function 3 hours
after administration, an effect that was sustained for 24 hours. The prolonged bradykinin-mediated vasorelaxation is principally
mediated through prostacyclin. ( J Am Heart Assoc. 2014;3:e000493 doi: 10.1161/JAHA.113.000493)
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T he peptide hormone relaxin is a renal and systemicvasodilator, increases global arterial compliance,
increases cardiac output, and mediates these parameters
during pregnancy in conscious rats.1,2 These animal studies
and later preclinical studies in compensated heart failure
patients, which showed that relaxin decreases pulmonary
capillary wedge pressure and systemic vascular resistance,3–5
suggested that serelaxin treatment results in rapid vasore-
laxation to improve the symptoms of heart failure. Indeed, a
recent phase III clinical trial (RELAXin in Acute Heart Failure
[RELAX-AHF]) demonstrated that a 48-hour infusion of
serelaxin (the recombinant form of human relaxin-2) to
patients admitted to hospital with acute heart failure resulted
in significant beneficial clinical outcomes. Specifically, serel-
axin improved dyspnoea relief, reduced in-hospital worsening
of acute heart failure, and decreased cardiovascular and all-
cause mortality at 180 days.6
Receptors for relaxin, RXFP1, are expressed in arteries and
veins and localized to both vascular smooth muscle cells and
the endothelium.7–9 Many studies have proposed an endothe-
lium-dependent mechanism to explain the vasodilator actions
of continuously infused relaxin on small renal arteries. This
involves increased vascular activity of matrix metalloprotein-
ases (MMP 2 and MMP 9), vascular endothelial growth factor,
and placental growth factor, leading to activation of endothelin
B receptors and nitric oxide (NO)-dependent vasodilation.10–13
Furthermore, a direct ex vivo vasodilator response to relaxin
has been demonstrated in human small resistance
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arteries.14,15 This is mediated by a rapid phosphatidylinositol-
3-kinase (PI3K) stimulation of protein kinase B (Akt) and
endothelial nitric oxide synthase (NOS) phosphorylation lead-
ing to increased endothelium-derived NO production.15 Relaxin
also increases coronary flow in rat and guinea pig hearts via
stimulation of NO production.16 The endothelium is an
important regulator of vascular tone, which in small resistance
arteries is influenced by endothelium-derived hyperpolariza-
tion (endothelium-derived hyperpolarizing factor [EDH])17 and
the release of NO and prostacyclin (PGI2).
18 However, no
studies to date have investigated if the actions of relaxin in the
systemic vasculature involve a contribution of PGI2 and EDH.
Time-course studies in preclinical models report that an
intravenous (IV) relaxin injection into the femoral vein
followed by long-term infusion increased glomerular filtration
rate within 1 to 2 hours, which is indicative of rapid onset of
renal vasodilation.19 The response to relaxin persisted in the
kidneys for 12 hours, but not at 24 hours, after infusion of
relaxin had ceased. However, the concentration of circulating
relaxin in the plasma was not reported; thus, it is unclear if the
sustained change in glomerular filtration rate in response to
relaxin treatment occurred in the presence or absence of
detectable circulating relaxin.19
There has been no preclinical assessment of the vascular
effects of a single bolus injection of serelaxin and the
persistence of a vasorelaxation response. Therefore, the aims
of the present study were to investigate changes in vascular
reactivity and passive mechanical wall properties of small
mesenteric arteries following a bolus IV injection of serelaxin
in vivo and to investigate whether these vascular effects are
sustained in the absence of detectable circulating serelaxin.
We also tested the hypothesis that in this small resistance
artery, the contribution of EDH and PGI2 to endothelium-
dependent relaxation is enhanced by serelaxin treatment.
Methods
All procedures were approved by the Faculty of Science
Animal Experimentation Ethics Committee (The University of
Melbourne) and conformed to the National Health and
Medical Research Council of Australia code of practice for
the care and use of animals for scientific purposes.
Intravenous Injection of Serelaxin
Male Wistar rats (300 to 400 g; Animal Resource Centre)
were randomly divided into 3 groups: (1) controls (n=47), (2)
3 hours (n=31) after serelaxin, and (3) 24 hours (n=26) after
serelaxin treatment. These 2 time points were chosen based on
pharmacokinetic modeling of serelaxin clearance in vivo, which
showed that circulating serelaxin levels persist at 3 hours but
not at 24 hours after serelaxin treatment (data not shown). For
drug administration, all animals were briefly anesthetized with
2% isofluorane and then maintained at 1% (Univentor 400;
Agnthos) in oxygen mix via inhalation. Once sedated, the rats
were placed on a heating pad (43°C), and a single bolus dose of
serelaxin (13.3 lg/kg) was injected into the tail vein, which is
equivalent to the standard infusion dosage of 4 lg/h.13,19 The
control groups received an equivalent volume of the placebo
(20 mmol/L sodium acetate). At either 3 or 24 hours post
serelaxin injection, blood samples were obtained from the left
ventricle via cardiac puncture under 2% isofluorane anesthesia.
Plasma concentrations of serelaxin were measured using the
Human Relaxin-2 Quantinine ELISA Kit (R&D Systems).
Isolation of Mesenteric Arteries
After blood collection, the animals were killed via cervical
dislocation. The mesenteric arcade was isolated and immedi-
ately placed in ice-cold Krebs bicarbonate solution containing
(in mmol/L) NaCl 120, KCl 5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25, D-glucose 11.1, and CaCl2 2.5, bubbled with 95%
O2 and 5% CO2. Small mesenteric arteries (third-order branch
of the superior mesenteric artery, internal diameter300 lm)
were isolated, cleared of fat and loose connective tissue, cut
into rings 2 mm in length, and mounted on a Mulvany-Halpern
wire-myograph (model 610M; Danish Myo Technology). The
remaining arteries were snap frozen in liquid nitrogen and
stored at 80°C for further analysis. After the arteries were
mounted on the myograph, the vessels were allowed to
stabilize at zero tension for 15 minutes before normalization,
as described previously.21,22 All experiments were performed
at 37°C, and the baths were bubbled with 95% O2 and 5% CO2.
Assessment of Vascular Reactivity
Vascular reactivity was performed as previously
described23,24 with the following modifications. Briefly, mes-
enteric arteries were maximally contracted with high K+
physiological saline solution (KPSS, 100 mmol/L), and the
integrity of the endothelium was determined, as described
previously.25 To evaluate the vascular smooth muscle reac-
tivity to vasoconstrictors, cumulative concentration-response
curves to endothelin-1 (ET-1, 0.1 nmol/L to 0.1 lmol/L) and
the thromboxane mimetic, U46619 (0.1 nmol/L to 1 lmol/
L), were constructed. In addition, constrictor responses to ET-
1 were examined after 20 minutes incubation with Nx-nitro-L-
arginine methyl ester (L-NAME, 200 lmol/L), a NOS inhibitor
and in endothelium-denuded vessels. Acute vasodilator
actions of serelaxin were determined by using cumulative
concentration-response curves to serelaxin (10 pmol/L to
0.3 lmol/L) in phenylephrine (0.1 to 3 lmol/L)-precontract-
ed mesenteric arteries. Similarly, to assess endothelial and
vascular smooth muscle function, mesenteric arteries were
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precontracted to a similar level (70% to 80% of KPSS
contraction) using phenylephrine (0.1 to 3 lmol/L), and
cumulative concentration-response curves to the endothe-
lium-dependent agonists acetylcholine (ACh; 0.1 nmol/L to
10 lmol/L) and bradykinin (BK; 0.1 nmol/L to 1 lmol/L),
intermediate conductance calcium-activated potassium chan-
nel (IKCa), small conductance calcium-activated potassium
channel (SKCa) opener NS309 (1 nmol/L to 10 lmol/L),
endothelium-independent agonists sodium nitroprusside
(SNP, 0.01 nmol/L to 10 lmol/L) and iloprost (1 pmol/L
to 0.1 lmol/L) were determined. In addition, responses to BK
were examined after 20 minutes of incubation with different
combinations of pharmacological blockers, including L-NAME
(200 lmol/L), the cyclooxygenase (COX) inhibitor indometh-
acin (Indo, 1 lmol/L), the IKCa inhibitor TRAM34 (1 lmol/L),
the SKCa inhibitor apamin (1 lmol/L), and a PGI2 synthase
inhibitor U51605 (1 lmol/L). The residual relaxation after
blockade of NOS and COX is attributed to EDH.26 The relative
contribution of NO, PGI2, and EDH to relaxation evoked by BK
was determined by analyzing the area under the curve (AUC) of
the BK-response curve.27 In brief, the response attributable to
the PGI2 was calculated by subtracting AUC in the presence of
Indo+L-NAME from that obtained in L-NAME alone. Similarly,
the component of the response mediated by NO was
determined by subtracting the AUC in L-NAME from the AUC
obtained in the absence of inhibitors. The AUC that remained in
the presence of Indo+L-NAME was attributed to EDH. Prosta-
noids have little or no contribution to ACh-induced relaxation in
rat mesenteric artery.28 Thus, for ACh-mediated relaxations, the
component of the relaxation attributed to NO was determined
by subtracting the AUC in the presence of Indo+L-NAME from
the AUC obtained in the absence of inhibitors. Similarly, the
component of relaxation mediated by EDH was the AUC that
remained in the presence of Indo+L-NAME.
Assessment of Basal NOS Activity
In a separate set of experiments, the effect of serelaxin
treatment on basal NO release was examined through the
addition of L-NAME (200 lmol/L) in endothelium-intact rings
submaximally contracted with phenylephrine (10 to
100 nmol/L) to 20% of KPSS contraction. Under these
conditions, a contractile response to L-NAME was considered
to reflect the level of basal NOS activity.29
Passive Mechanical Wall Properties
At 24 hours after serelaxin injection, mesenteric, femoral, and
renal arteries were transferred to Ca2+-free EGTA (2 mmol/L)
containing Krebs-HEPES buffer (Ca2+-free PSS), pH 7.4, until
mounted on a pressure myograph (Living Systems Instrumen-
tation). Leak-free segments (3 to 4 mm in length) of artery
were then mounted on a glass cannula (tip diameter
200 lm) filled with Ca2+-free PSS. The lumen was gently
flushed to remove any remaining blood, and then the distal
end was tied off to prevent flow. The arteries were bathed in
Ca2+-free PSS warmed to 37°C. After a 20-minute equilibra-
tion period, intraluminal pressure was increased from 0 to
190 mm Hg, in 10–mm Hg increments. The vessel length,
outside diameter (OD), and wall thickness (WT) were
measured at each pressure step. Inside diameter (ID) was
calculated by subtracting the WT from the OD. Wall stress and
strain were derived from the following calculations: wall stress
(kPa)=(intraluminal pressure9ID)/(29WT); wall strain=(IDID
extrapolated to 5 mm Hg pressure)/(ID extrapolated to
5 mm Hg pressure), as described previously.7 For normaliza-
tion of ID and OD, values were expressed as: (value at current
pressurevalue at 5 mm Hg)/(value at 5 mm Hg). Volume
compliance was calculated for each pressure increment using
the following calculation: volume compliance=(D volume)/(D
pressure), where D volume=(D cross-sectional area)9(D
length), where cross-sectional area=(p•ID2)/4.
Western Blotting
Western blots were performed as described previously23 with
the following modifications. Frozen endothelium-intact mesen-
teric arteries were placed in a prechilled Wig-L-Bug capsule with
a metal silver ball and pulverized in a Digital Wig-L-Bug
amalgamator (Dentsply Ltd). The samples were dissolved in
300 lL of ice-cold lysis buffer (100 mmol/L NaCl, 10 mmol/L
Tris, 2 mmol/L EDTA, 0.5% w/v sodium deoxycholate, 1% vol/
vol Triton X-100, pH 7.4, protease, and phosphatase inhibitor
cocktails (Roche)), and the total protein concentration of
the samples was quantified using a BCA protein assay kit
(ThermoScientific). Equal amounts of protein homogenate were
subjected to SDS-PAGE andWestern blot analysis with mouse/
rabbit primary antibodies (all 1:1000, overnight, 4°C) against
Akt, phospho-Ser473 Akt (all Cell Signalling) and inducible NOS
(iNOS), endothelium NOS (eNOS), and phospho-Ser1177 eNOS
(all BD Transduction Laboratories). To normalize for the amount
of protein, membranes were reprobed with a loading control
antibody (actin). All proteins were detected by using enhanced
chemiluminescence (Amersham, GE Healthcare Life Sciences)
after incubation with anti-mouse/rabbit secondary antibody
(Millipore) for 1 hour at room temperature (1:2000). All protein
bands were quantified by using densitometry (Biorad Chemi-
doc) and expressed as a ratio of the loading control.
RNA Extraction and Quantitative Polymerase
Chain Reaction
Frozen blood vessels were pulverized as described here
earlier. Pulverized tissues were resuspended in 1 mL
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TriReagent (Ambion Inc), and total RNA was then extracted
according to the manufacturer’s instructions. RNA pellets were
resuspended in 15 to 20 lL RNA Secure (Ambion). Quality and
quantity of RNA were analyzed using the NanoDrop ND1000
Spectrophotometer (Thermo Fisher Scientific Australia Pty Ltd)
with A260:A280 ratios greater than 1.8, indicating sufficient
quality for quantitative real-time polymerase chain reaction
(qPCR) analysis. First-strand cDNA synthesis used 1 lg of
total RNA in a 20-lL reaction containing random hexamers
(50 ng/lL) and 200 units of Superscript III (Invitrogen). The
comparative cycle threshold (2DCT) method of qPCR was
used to analyze cyclooxygenase 1 (Ptgs1) and 2 (Ptgs2), PGI2
synthase (Ptgis), and receptor (Ptgir), BK type 2 receptor
(Bdkrb2, Bdkrb2v1), and eNOS (Nos3) gene expression in
serelaxin and placebo-control rats. Rat-specific forward/
reverse primers and 6-carboxyl fluorescein–labeled (FAM)
Taqman probes were designed and purchased from Biosearch
Technologies. Primers were designed to span intron/exon
boundaries. qPCR was performed on the AB Applied Biosys-
tems ViiA7 PCR machine (Life Technologies) using 96-well
reaction plates with 10-lL volume reactions in triplicate
containing SensiMix (Bioline) and 10 lmol/L primers and
FAM-labeled probe. Ribosomal 18S (Rn18s) was the reference
gene. Negative template controls substituting cDNA with
water or reverse transcriptase negative controls substituting
the reverse transcriptase in the cDNA synthesis, were included
on each plate. For each sample, the mean Rn18s CT triplicate
value was subtracted from the mean gene of interest triplicate
CT value to normalize gene of interest expression to the
reference gene. These normalized data (DCT) were then
presented as a relative value (meanSEM).
Reagents
All drugs were purchased from Sigma-Aldrich, except for ET-1
and BK (Auspep) and U46619 (Cayman Chemical). All drugs
were dissolved in distilled water, with the exception of Indo,
which was dissolved in a 0.1 mol/L sodium carbonate, and
U46619, which was dissolved in 100% ethanol (final concen-
tration <0.1% ethanol) as 1 mmol/L stock solution, and
subsequent dilutions were in distilled water.
Statistical Analyses
All results are expressed as the meanSEM, and n represents
the number of animals per group or the number of assays
when tissues from animals were pooled. Concentration-
response curves for rat mesenteric arteries were computer
fitted to a sigmoidal curve using nonlinear regression (Prism
version 5.0; GraphPad Software) to calculate the sensitivity of
each agonist (pEC50). Concentration-response curves were
also analyzed with the use of repeated-measures 2-way
ANOVA (treatment versus concentration). Maximum relaxa-
tion (Rmax) to vasodilators was measured as a percentage of
precontraction to phenylephrine. Group pEC50 and Rmax
values were compared via 1-way ANOVA with post-hoc
analysis using Dunnett’s test or Student’s unpaired t test as
appropriate. Stress-strain curves were analyzed with the use
of repeated-measures 2-way ANOVA (treatment versus
strain). P<0.05 was considered statistically significant.
Results
Serelaxin Reduced ET1-Mediated Contraction 3
Hours After IV Injection in the Mesenteric Artery
Plasma serelaxin was detected 3 hours after serelaxin
injection (range 1.23 to 4.17 ng/mL, mean 2.33 ng/mL)
but was undetectable after 24 hours. Contraction evoked by
KPSS (100 mmol/L) was not affected by serelaxin treatment
at either time point (Figure S1). The direct vasorelaxant
effects of serelaxin are shown in Figure S2. Responses to
cumulative addition of serelaxin were not significantly differ-
ent from the time control, indicating that acute serelaxin
application did not produce a relaxation in the rat mesenteric
artery. Maximum contraction, but not sensitivity to ET1, was
significantly (P<0.001) reduced by 1.35-fold 3 hours after
serelaxin injection (Figure 1A). Suppression of the ET1
contraction was not sustained, and by 24 hours after
serelaxin treatment, contraction amplitude was comparable
to that of mesenteric arteries from placebo-treated rats. To
investigate if NO released from the endothelium suppressed
maximum contraction to ET1 3 hours after serelaxin injection,
ET1 responses were evaluated in the presence of L-NAME and
in endothelium-denuded mesenteric arteries. The maximum
contraction to ET1 was not different between placebo and
serelaxin-treated groups after blockade of NOS (Figure 1B)
and endothelium removal (Figure 1C), confirming that endo-
thelium-derived NO mediated the reduction in the maximum
contraction to ET1 3 hours after serelaxin injection.
IV Serelaxin Injection Selectively Improved BK-
Evoked Endothelium-Dependent Relaxation in the
Mesenteric Artery
Endothelium-dependent relaxation is mediated by multiple
factors, including NO,30,31 PGI2,
18 and EDH.17 To evaluate
whether serelaxin enhances endothelial vasodilator function,
vascular reactivity to 2 different endothelium-dependent
agonists, ACh and BK, were determined. There was no
significant effect of serelaxin on the sensitivity and maximum
relaxation to ACh at either 3 or 24 hours after injection
(Figure 2A). In contrast, the sensitivity, but not maximum
relaxation, to BK was significantly increased by 4.5-fold
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after 3 hours (P<0.01) and by 6.08-fold at 24 hours
(P<0.001) after serelaxin injection (Figure 2B).
To explore whether serelaxin injection alters the mecha-
nism of ACh-induced relaxation, vascular reactivity to ACh was
evaluated in the presence of the combination of COX and NOS
inhibitors Indo+L-NAME. In all groups, the presence of these
inhibitors significantly shifted the ACh-response curve to the
right (Figure S3A) without affecting maximum relaxation to
ACh. Because there is little or no contribution of PGI2 to ACh-
mediated endothelium-dependent relaxation in the rat mes-
enteric artery,28 we only assessed the contribution of NO and
EDH. In the presence of Indo+L-NAME, the sensitivity (Figure
S3B) and maximum relaxation (Figure S3C) to ACh were similar
between the groups of rats, indicating that serelaxin had no
effect on the contribution of EDH to ACh-induced relaxation.
Similarly, AUC analysis of ACh-response curves revealed that
the relative contribution of NO and EDH in ACh-evoked
relaxation was unaffected by serelaxin treatment (Figure S3D).
We then investigated endothelial factors associated with
the enhanced BK-induced relaxation after serelaxin injection.
Responses to BK were obtained in the presence of either
L-NAME alone or the combination of Indo+L-NAME. In all
groups, including the placebo, the presence of L-NAME alone
or the combination of Indo+L-NAME significantly shifted the
BK-response curve to the right (Figure 3A). Thus, the sensi-
tivity to BK was significantly reduced, but maximum relaxation
was unaltered in mesenteric arteries. Blockade of COX activity
had no effect on the BK-response curve in rats treated with
placebo or 3 hours after serelaxin injection. However, at
24 hours after serelaxin, the addition of Indo to L-NAME
caused a significant rightward shift of the BK-response curve
compared with L-NAME alone (Figure 3A). This suggests a role
of vasodilator prostanoids in mesenteric arteries 24 hours
after serelaxin treatment.
In the presence of L-NAME, the sensitivity to BK was
significantly (P<0.05) increased in arteries at 3 and 24 hours
after serelaxin injection compared with those from placebo-
treated rats. In the presence of Indo and L-NAME, the
sensitivity to BK remained significantly (P<0.05) increased
3 hours after serelaxin (Figure 3B), indicating that serelaxin
treatment improves BK-dependent EDH-type relaxation. Con-
versely, the sensitivity to BK after 24 hours serelaxin was


































































































Figure 1. At 3 hours post serelaxin treatment, reduced ET1 induced contraction through endothelium-derived NO pathway. Concentration-
response curves, sensitivity (pEC50), and maximal responses to ET1. Responses in the (A) absence or (B) presence of L-NAME in endothelium-
intact mesenteric and (C) endothelium-denuded arteries isolated from (●) placebo, (□) at 3 hours, and (▲) at 24 hours after a single bolus
injection of serelaxin (n=4 to 8 per group). ***P<0.001 (1-way ANOVA, Dunnett’s post-hoc test). ET1 indicates endothelin-1; L-NAME, Nx-nitro-
L-arginine methyl ester; NO, nitric oxide; pEC50, negative log of half-maximal effective concentration.
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attenuated to a level that was comparable to that of placebo-
treated rats (Figure 3B) with the blockade of NOS and COX,
indicating no prolonged involvement of EDH. Analysis of the
AUC of the BK-response curves to reveal the relative
contribution of NO, EDH and COX also demonstrated that
EDH-type and COX-mediated relaxation were augmented at 3
and 24 hours after serelaxin injection (Figure 3D).
In a separate series of experiments, the relative contribu-
tion of IKCa and SKCa channels underlying the augmented BK-
evoked EDH-type relaxation was investigated 3 hours after
serelaxin injection using TRAM34 and apamin, respectively.
The sensitivity of BK was significantly (P<0.05) increased
3 hours after serelaxin injection in the absence of inhibitors
(Figure 4A) and in the presence of Indo+L-NAME (Figure 4B).
In contrast, the sensitivity and maximum relaxation to NS309
were not significantly altered 3 hours after serelaxin injection
(Figure 4C). In the presence of Indo+L-NAME+apamin, the
sensitivity (pEC50 7.740.24 versus 7.040.14) to BK was
significantly (P<0.05) increased 3 hours after serelaxin injec-
tion (Figure 4D). Conversely, in the presence of Indo+L-
NAME+TRAM34, maximum relaxation (Rmax 2617% versus
7311%) to BK was significantly (P<0.05) reduced 3 hours
after serelaxin injection (Figure 4E). The relaxation response
evoked by BK was abolished in both placebo- and serelaxin-
treated mesenteric arteries in the combined presence of
Indo+L-NAME+apamin+TRAM34 (Figure 4F).
The involvement of PGI2 as the vasodilator prostanoid
factor responsible for the improvement of BK-mediated
relaxation at 24 hours after serelaxin injection was elucidated
using a selective PGI2 synthase inhibitor, U51605. In
Figure 5A, sensitivity to BK was significantly (P<0.05)
increased 24 hours after serelaxin injection, which was
abolished by the presence of Indo (Figure 5B) and U51605
(Figure 5C). Similarly, in the presence of L-NAME, the
sensitivity to BK remained significantly (P<0.05) increased
24 hours after serelaxin injection (Figure 5D) and was
abolished in the presence of L-NAME+U51605 (Figure 5E).We
further explored the mechanisms underlying the improvement
of BK-dependent PGI2-mediated relaxation 24 hours after
serelaxin injection by analyzing the expression of genes
associated with PGI2 synthesis pathways. There was no effect
of serelaxin on COX2 (Pgts2) or PGI2 synthase (Ptgis,
Figure 6A and 6B) expression in mesenteric arteries at either
time points. COX1 (Ptgs1) mRNA expression was not
















































































































Figure 2. Serelaxin treatment selectivity enhances sensitivity to BK-induced relaxation. Concentration–response curves, sensitivity (pEC50),
and maximum relaxation (Rmax) to (A) ACh and (B) BK in endothelium-intact mesenteric arteries isolated from (●) placebo, (□) at 3 hours, and
(▲) at 24 hours after a single bolus injection of serelaxin (n=8 to 10 per group). **P<0.01, ***P<0.001 (1-way ANOVA, Dunnett’s post-hoc
test). ACh indicates acetylcholine; BK, bradykinin; pEC50, negative log of half-maximal effective concentration.
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determined (CT>40 cycles) in mesenteric arteries (data not
shown). The enhancement of PGI2-mediated response by
serelaxin treatment could be due to an increase in the
sensitivity to PGI2 receptors and/or upregulation of their
expression. As described earlier, smooth muscle sensitivity and
maximum response to the PGI2 analog iloprost were unaltered
(Figure 8C). Similarly, serelaxin had no effect on Ptgir gene
expression at both time points (Figure 6C). There was also no
effect in BK type 2 receptors (Bdkrb2v1 and Bdkrb2) after
serelaxin treatment at either time point (Figure 6E and 6F).
IV Serelaxin Injection Increased Basal NOS
Activity After 3 Hours but Produces Sustained
Akt Phosphorylation After 24 Hours in the
Mesenteric Artery
Basal NOS activity was assessed by measuring the
contraction induced by L-NAME in arteries with a low
level of phenylephrine-induced tone.23,29 The L-NAME–
induced contraction was significantly (P<0.05) greater in
arteries 3 hours after serelaxin injection compared with
those of placebo-treated rats (Figure 7A), indicating that
basal NOS activity was increased. This effect was not
observed in arteries 24 hours after serelaxin treatment. At
3 hours after serelaxin treatment, there was a significant
(P<0.05) increase in phosphorylation of Aktser473 in the
mesenteric arteries that was sustained for 24 hours
(P<0.001) (Figure 7B). Total Akt protein expression was
not affected by serelaxin treatment at either time point
(Figure 7C). Interestingly, phosphorylation of eNOSser1177
(Figure 7D) and upregulation of iNOS protein (Figure 7F) in
the mesenteric arteries was only significantly increased at
24 hours, but not at 3 hours, after serelaxin injection.
Total eNOS gene (Figure 6D) and protein (Figure 7E)
expression was not affected by serelaxin treatment at
any time point.





















































































































Figure 3. Serelaxin treatment causes time-dependent augmentation of the contributions of EDH and PGI2 to BK-induced relaxation.
Concentration–response curves to BK in the absence (control, ●) or presence of L-NAME (■, NOS inhibitor), Indo+L-NAME (▲, inhibitors of COX
and NOS) in endothelium-intact mesenteric arteries isolated from (A) placebo, at 3 hours, and at 24 hours after a single bolus injection of
serelaxin-treated rats. #P<0.05 vs control, WP<0.05 vs L-NAME (2-way repeated-measures ANOVA). Mesenteric (B) sensitivity (pEC50) and (C)
maximum relaxation (Rmax) to BK in (filled bars) placebo, (open bars) at 3 hours, and (striped bars) at 24 hours after a single bolus injection of
serelaxin. Area under curve (D) of BK-response curve reveals the relative contribution of NO, EDH, and COX (n=6 to 7 per group). *P<0.05,
***P<0.001 (1-way ANOVA, Dunnett’s post-hoc test). BK indicates bradykinin; COX, cyclooxygenase; EDH, endothelium-derived hyperpolar-
ization; Indo, indomethacin; L-NAME, Nx-nitro-L-arginine methyl ester; NOS, nitric oxide synthase; pEC50, negative log of half-maximal effective
concentration; PGI2, prostacyclin.
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IV Serelaxin Injection Had No Effect on
Endothelium-Independent Vasoconstrictor and
Vasodilator Function
Injection with serelaxin had no effect on the sensitivity or
maximal response to the vasoconstrictor thromboxane
mimetic U46619 (Figure 8A) at 3 hours, nor on the actions
of the endothelium-independent vasodilators SNP (Figure 8B)
at either time point, or by iloprost (Figure 8C) at 24 hours
after a bolus IV injection.
IV Serelaxin Injection Had No Effect of Passive
Mechanical Wall Properties of the Mesenteric,
Saphenous, and Renal Arteries
Chronic infusion of serelaxin has been demonstrated to
regulate vascular wall remodeling and passive mechanical wall
properties.9,32 We sought to investigate whether this effect
could be observed with a bolus injection of serelaxin. In
mesenteric arteries, serelaxin treatment had no significant
effect on passive wall stiffness (Figure 9A) or volume
compliance (Figure 9B) across the pressurization range
compared with placebo-treated rats 24 hours after injection.
Furthermore, there was no significant differences in OD
(Figure 9C) or normalized OD, ID, and WT (Figure 9D). The
effects of serelaxin on the passive stiffness of arteries from
other vascular beds were also examined. As with the
mesenteric arteries, the stress-strain relationships for saphe-
nous and renal arteries from placebo- and serelaxin-treated
rats were comparable (Figure S4), indicating there was no
effect of serelaxin on passive wall stiffness.
Discussion
This study demonstrated that a single IV injection of serelaxin
modulated endothelial vasodilator function 3 hours after
administration. We suggest that serelaxin activated RXFP1
localized to endothelial cells and caused an increase in



































































































Figure 4. Involvement of IKCa channel in BK-induced EDH-type relaxation 3 hours after serelaxin injection. Concentration–response curves to
BK in the (A) absence or (B) presence of Indo+L-NAME, (D) Indo+L-NAME+apamin, (E) Indo+L-NAME+TRAM34, and (F) Indo+L-
NAME+TRAM34+apamin in endothelium-intact mesenteric arteries isolated from (●) placebo and (□) at 3 hours after a single bolus injection
of serelaxin. Concentration–response curves to (C) NS309 in the endothelium-intact mesenteric arteries isolated from (●) placebo and (□) at
3 hours after a single bolus injection of serelaxin-treated rats (n=6 to 10 per group). *pEC50 significantly different from placebo, P<0.05
#maximum relaxation significantly different from placebo (P<0.05) (1-way ANOVA, Dunnett’s post-hoc test). BK indicates bradykinin; EDH,
endothelium-derived hyperpolarization; IKca, intermediate conductance calcium-activated potassium channel; Indo, indomethacin; L-NAME, Nx-
nitro-L-arginine methyl ester; TRAM34, (1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole) pEC50, negative log of half-maximal effective
concentration.
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AktSer473 phosphorylation and basal NOS activity. Serelaxin
also selectively enhanced BK-mediated endothelium-depen-
dent relaxation in rat mesenteric arteries. Although circulating
levels of serelaxin were not detected 24 hours after bolus
injection, the effect on BK-mediated relaxation was sustained.
Our findings indicate that the vasorelaxant effects of BK,
which are potentiated by serelaxin, are mediated by different
endothelium-derived relaxing factors over time. Specifically,
serelaxin-mediated augmentation of BK-evoked relaxation
involves IKCa-dependent EDH-type relaxation at 3 hours and
PGI2-mediated relaxation at 24 hours. Furthermore, Akt
remains phosphorylated at Ser473, with increased eNOS
phosphorylation at Ser1177 and an upregulation in iNOS
expression 24 hours after IV serelaxin injection.
Previous animal studies have shown a rapid vasodilator
response to relaxin in resistance arteries,15 but it remains
unclear how long these effects are sustained, especially to a
bolus IV injection. Acute injection followed by long-term IV
infusion of relaxin increased glomerular filtration rate, which
was sustained for 12 hours, but not 24 hours, after treatment
in rats.19 It is important to note that in that study, serum
levels of relaxin between 1 and 6 ng/mL produced physio-
logical changes in the kidney, suggesting that our reported
concentration of relaxin (2.33 ng/mL) was sufficient to
produce a vasorelaxation. However, a direct effect of relaxin
on the renal artery vascular function after a bolus relaxin
injection was not explored. In the present study, we
demonstrated that a single IV injection of serelaxin selectively
improved endothelial function in the presence of circulating
serelaxin (after 3 hours), as observed by an augmentation of
endothelium-dependent relaxation, without affecting endothe-
lium-independent relaxation. Furthermore, enhanced endo-
thelial function was agonist specific, as serelaxin treatment
had no effect on ACh-evoked responses but improved BK-
mediated responses. In rat aortic rings treated in vitro with
tumor necrosis factor-a, coincubation with relaxin improved
ACh-mediated relaxation.33 This suggests that relaxin may
have differential effects in conduit (aorta) versus resistance
arteries (mesenteric artery) or that its actions are more
pervasive under disease conditions. Although RXFP1 are
expressed in the endothelial and vascular smooth muscle
cells,7,9 the vascular actions of serelaxin after a single IV















































































Figure 5. Involvement of PGI2 in BK-induced relaxation 24 hours after serelaxin injection. Concentration–response curves to BK in the (A)
absence or presence of (B) Indo, (C) U51605, (D) L-NAME, and (E) U51605+L-NAME in endothelium-intact mesenteric arteries isolated from (●)
placebo and(▲) at 24 hours after a single bolus injection of serelaxin (n=6 to 7 per group). *pEC50 significantly different from placebo, P<0.05
(1-way ANOVA, Dunnett’s post-hoc test). BK indicates bradykinin; Indo, indomethacin; L-NAME, Nx-nitro-L-arginine methyl ester; pEC50, negative
log of half-maximal effective concentration; PGI2, prostacyclin.
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injection appear mainly to be limited to the endothelium as
serelaxin treatment had no effect on endothelium-indepen-
dent relaxation (SNP and iloprost) and contraction (U46619).
The rapid vascular actions of relaxin are consistent with
studies that have demonstrated that relaxin acts on RXFP1 on
endothelial cells9 and causes endothelium-dependent relaxa-
tion of human and rodent renal arteries.14,15 However, it is
important to note that the direct effect of relaxin is artery
specific as serelaxin did not produce vasorelaxation in rat
mesenteric arteries when applied cumulatively ex vivo in the
organ bath. One proposed endothelium-dependent mecha-
nism for the vasodilator action of relaxin involves activation of
ETB receptors and an increase in NO production in resistance
arteries.34 Our functional data also indicate that, 3 hours after
serelaxin injection, there is a reduction in the maximum
contraction to ET1. Consistent with earlier observations,34
this effect was abolished by the NOS inhibitor L-NAME and
endothelium removal, indicating that endothelium-derived NO
was involved in the suppression of maximum contraction to
ET1. In our study, we also demonstrated that at 3 hours after
a single IV injection of serelaxin, there was an increase in
basal NOS activity. This suggests that serelaxin may alter the
activity of eNOS to increase production of NO. Activation of
eNOS is regulated by several protein kinases,35 including
Akt.36 The level of phosphorylation of Akt on Ser473 was
increased after 3 hours of serelaxin injection, without affect-
ing total expression of Akt, eNOS, or, interestingly,
eNOSser1177. Similarly, studies in cultured endothelial cells
also demonstrated that serelaxin activates PI3K, leading to
the phosphorylation of Aktser473 and eNOSser1177 and result-
ing in the generation of NO. Furthermore, 48 hours of relaxin
treatment of organ-cultured rat aortic rings ex vivo augmented
eNOS activity but not expression via enhanced phosphoryla-
tion at Ser1177 and Ser633 and dephosphorylation at
Thr495.33 Collectively, these observations indicate that
3 hours after a single injection of serelaxin, there were
significantly increased levels of Akt phosphorylation, actions
that would cause eNOS activation, probably through other
eNOS phosphorylation sites (independent of eNOSser1177),
and increase NO synthesis.36
Despite the many reports showing that relaxin has
sustained effects on the vascular system, the vasodilator
effects of relaxin in vivo are always studied in the continuous
presence of circulating relaxin.9,19,37 There is a paucity of
information regarding sustained vascular function in the

















































































































































































Figure 6. Serelaxin treatment had no effect on gene expression. Quantitative analysis of (A) Ptgs2, (B) Ptgis, (C) Ptgir, (D) NOS3 (E) Bdkrb2v1,
and (F) Bdkrb2 expression in mesenteric arteries from rats at 3 and 24 hours after a single injection of (filled bars) placebo and (filled bars)
serelaxin (n=7 to 8 per group). Values are 2DCtSEM. NOS indicates nitric oxide synthase.
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study, we evaluated vascular function of mesenteric arteries
24 hours after a single IV injection of serelaxin, where there is
no detectable circulating level of serelaxin. Consistent with
our earlier observation at the 3-hour time point, we found
that, in the absence of serelaxin, there is augmentation of
endothelium-dependent relaxation without affecting endothe-
lium-independent relaxation. At the 24-hour time point,
however, we do not observe any changes in ET1 responses
or basal NOS activity, indicating that these effects may occur
only in the presence of circulating serelaxin. Interestingly, the
level of phosphorylation of Akt on Ser473 remains increased
24 hours after serelaxin injection, without affecting total Akt
expression in the mesenteric artery. In addition, at this time
point, there is an increase in phosphorylation of eNOS on
Ser1177 and upregulation of iNOS expression. Taken
together, our data show that the direct and rapid effect of
serelaxin on the endothelium requires circulating levels of
serelaxin. However, serelaxin improves BK-mediated endothe-
lium-dependent relaxation, an effect that is sustained in the
absence of a circulating level of serelaxin.
Endothelium-dependent relaxation is mediated by multiple
factors, including NO,30,31 PGI2,
18 and EDH.17 We further
investigated the mechanisms underlying the augmentation of
BK-mediated endothelium-dependent relaxation at 3 and
24 hours after a single bolus of serelaxin. Three hours after
serelaxin treatment, when serelaxin is still present in the
circulation, EDH-type relaxation is upregulated. However, at
the 24-hour time point, when circulating levels of relaxin have
Figure 7. Serelaxin treatment increased basal NOS activity after 3 hours but produces sustained Akt phosphorylation from 3 to 24 hours in
the mesenteric artery. (A) Basal NOS activity in endothelium-intact mesenteric arteries isolated from (filled bars) placebo, (open bars) at 3 hours,
and (striped bars) at 24 hours after a single bolus injection of serelaxin. In each group of experiments, mesenteric arteries were precontracted
with phenylephrine to similar levels (placebo 212%, 3 hours serelaxin 201%, and 24 hours serelaxin 221% of KPSS) before the addition of
L-NAME (NOS inhibitor) (n=6 to 8 per group). Western blot analysis of pAktser473 (B, 60 kDa), total Akt (C, 60 kDa), peNOSser1177 (D, 140 kDa),
total eNOS (E, 140 kDa), and iNOS (F, 140 kDa) protein expression in mesenteric arteries from (filled bars) placebo, (open bars) at 3 hours, and
(striped bars) at 24 hours after a single bolus injection of serelaxin. Representative blots are shown in the figure (n=4 to 6 per group). *P<0.05,
***P<0.001 (1-way ANOVA, Dunnett’s post-hoc test). Akt indicates protein kinase B; eNOS, endothelial nitric oxide synthase; iNOS, inducible
nitric oxide synthase; KPSS, K+ physiological saline solution; L-NAME, Nx-nitro-L-arginine methyl ester; NOS, nitric oxide synthase peNOS,
phosphorylated NOS.
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declined below detection, the response attributed to a
vasodilator prostanoid, presumably PGI2 was augmented. In
the rat mesenteric artery, EDH responses are generated by
contact mediated (myoendothelial gap junctions) and non–
contact-mediated mechanisms.26,38 Generation of EDH
involves the opening of endothelial IKCa and SKCa channels
and subsequent hyperpolarization and relaxation of smooth
muscle cells.39–42 The relative contribution of IKCa and SKCa
channels in responses to serelaxin treatment was elucidated
using pharmacological inhibition. In the presence of apamin
(Indo+L-NAME), the residual BK-induced relaxation is attrib-
uted to IKCa channels, and we demonstrated that BK response
was significantly increased 3 hours after serelaxin injection.
Similarly, in the presence of TRAM34 (Indo+L-NAME), the
maximum relaxation to BK was reduced in mesenteric arteries
of serelaxin-treated rats, indicating that the upregulation of
BK-evoked EDH-type relaxation involves IKCa, but not SKCa,
channels. The combination of apamin and TRAM34 abolished
BK-mediated relaxation, suggesting that BK-mediated EDH-
type relaxation is entirely dependent on IKCa and SKCa
channels. To date, there is limited evidence of the effects of
relaxin on EDH-type responses. A recent study in rats43
demonstrated that long-term treatment (10 days) with relaxin
(circulating levels 588 ng/mL) suppressed myogenic tone
in pressurized parenchymal arterioles via a mechanism
involving IKCa channels. This suggests that long-term expo-
sure to relaxin might be upregulating basal EDH responses.
Although we examined EDH-mediated relaxation evoked by BK
rather than the contribution of EDH to basal tone, both
studies provide evidence that in the presence of circulating




























































































































































Figure 8. Serelaxin had no effect on endothelium-independent vasoconstrictor and vasodilator function. Concentration-response curves,
sensitivity (pEC50) and maximal responses to (A) U46619, (B) SNP, and (C) iloprost in endothelium-intact mesenteric arteries isolated from (●)
placebo, (□) at 3 hours, and (▲) at 24 hours after a single bolus injection of serelaxin (n=5 to 8 per group). pEC50 indicates negative log of half-
maximal effective concentration; SNP, sodium nitroprusside.
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relaxin, the responses attributed to EDH are upregulated.
Interestingly, responses to the opener of IKCa and SKCa
channels, NS309, was not affected 3 hours after serelaxin
injection, suggesting that the augmentation of EDH-type
relaxation involved a signaling mechanism through the BK
receptor, rather than activity of the IKCa and SKCa channels.
This phenomenon is also reported in a recent study of SHR
rats,44 where long-term relaxin treatment had minimal effect
in improving NS309 responses in hypertensive parenchymal
arterioles. EDH is an important vasodilator mechanism in
small arteries and arterioles and may be an additional
mechanism by which relaxin reduces peripheral vascular
resistance.
To determine the mechanism underpinning the prolonged
action of serelaxin, vascular function was analyzed from rats
at 24 hours post serelaxin treatment, where there was no
detectable circulating level of serelaxin. Our data indicate
upregulation of PGI2 24 hours after serelaxin treatment, as
this response was abolished by blockade of COX and PGI2S.
Synthesis of PGI2 involves a cascade of enzymes such as
COX1, COX2, and PGI2 synthase, which stimulates smooth
muscle PGI2 receptors, leading to accumulation of cAMP and
vasodilation.18,45 Analysis of mRNA expression revealed that
serelaxin treatment had no effect on Ptgs2, Ptgis, or Ptgir.
Furthermore, serelaxin treatment did not enhance the sensi-
tivity or maximum response to iloprost. Taken together, our
findings suggest that the sustained vasorelaxant effect of
serelaxin is likely to be mediated by endothelium-dependent
mechanisms, possibly through increasing the activities of
enzymes rather than expression. Because the mRNA expres-
sion of COX1 (Ptgs1) was not determined (expression too low)
in the mesenteric arteries, it is likely that the augmentation of
BK-induced PGI2-mediated relaxation is dependent on COX-2
expression/activity. Indeed, relaxin treatment for 24 hours
has been shown to increase expression of COX2 in normal
human endometrial stromal cells.46 In our study, we demon-
strated that Akt and eNOS were phosphorylated and that
iNOS expression was upregulated in mesenteric arteries
24 hours after IV serelaxin injection, which could be due to
Akt activation. This finding is also reported in a recent
study,47 which demonstrated that relaxin (5 lg/kg, IV)
infusion protects against ischemia-reperfusion injury through
the activation of Akt and upregulation of iNOS in the rat
kidney.
It is well known that long-term subcutaneous relaxin
infusion promotes compositional and geometric remodeling
of blood vessels, resulting in increased vascular compliance
in small renal, uterine, and mesenteric arteries.9,32,48,49

















































































































Figure 9. Serelaxin treatment had no effect on passive mechanical wall properties in the mesenteric artery. Stress-strain relationships (A) and
relationships for volume compliance (B), outer diameter (C), and normalized inside (ID) and outside diameters (OD) and wall thickness (WT; D)
against intraluminal pressures in mesenteric arteries isolated from (●) placebo and (○) at 24 hours after serelaxin. Values are meanSEM (n=5
to 8 per group).
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Specifically, in mice treated with 1 lg/h relaxin for 5 days,
there was an increase in unpressurized wall area and WT-to-
lumen area ratio and smooth muscle cell density and a
decrease in collagen-to–total protein in small renal artery.20
In the present study, our data showed that 24 hours after a
single injection of serelaxin, there was no effect on vessel
dimensions and stress-strain relationships in mesenteric
arteries, indicating that serelaxin had no short-term effect
on passive wall stiffness. Similar observations were made in
saphenous and renal arteries. Hence, we hypothesize that
24 hours is an insufficient time frame to cause sufficient
vascular wall remodeling that would translate into changes
in passive wall stiffness and compliance. Another possibility
is that the duration of time and concentration of circulating
serelaxin that is present after a single bolus dose of
serelaxin may not be sufficient to stimulate vascular wall
remodeling.
The present study has important clinical implications in
that a single IV injection of serelaxin can elicit rapid effects on
the endothelium and augment vasorelaxation actions of BK
that are prolonged for at least 24 hours, even after circulating
levels of relaxin have diminished. This initially involves EDH
and NO, but the prolonged 24-hour response is attributed
to PGI2.
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